Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of MLN8237 when given
together with erlotinib hydrochloride and to see how well it works in treating patients with
recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). MLN8237 and
erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.